Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 5104-49-4 Chemical Structure| 5104-49-4

Structure of Flurbiprofen
CAS No.: 5104-49-4

Chemical Structure| 5104-49-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Flurbiprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.

Synonyms: dl-Flurbiprofen; Ansaid; Flurbiprofen, Ansaid, Froben, Cebutid, Antadys

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Tonduru, Arun Kumar ; Maljaei, Seyed Hamed ; Adla, Santosh Kumar ; Anamea, Landry ; Tampio, Janne ; Kralova, Adela , et al.

Abstract: OATP1C1 (organic anion-transporting polypeptide 1C1) transports thyroid hormones, particularly thyroxine (T4), into human astrocytes. In this study, we investigated the potential of utilizing OATP1C1 to improve the delivery of anti-inflammatory drugs into glial cells. We designed and synthesized eight novel prodrugs by incorporating T4 and 3,5-diiodo-L-tyrosine (DIT) as promoieties to selected anti-inflammatory drugs. The prodrug uptake in OATP1C1-expressing human U-87MG glioma cells demonstrated higher accumulation with T4 promoiety compared to those with DIT promoiety or the parent drugs themselves. In silico models of OATP1C1 suggested dynamic binding for the prodrugs, wherein the pose changed from vertical to horizontal. The predicted binding energies correlated with the transport profiles, with T4 derivatives exhibiting higher binding energies when compared to prodrugs with a DIT promoiety. Interestingly, the prodrugs also showed utilization of oatp1a4/1a5/1a6 in mouse primary astrocytes, which was further supported by docking studies and a great potential for improved brain drug delivery.

Purchased from AmBeed: ; ; ; ; ; 5104-49-4 ; 22204-53-1

Alternative Products

Product Details of Flurbiprofen

CAS No. :5104-49-4
Formula : C15H13FO2
M.W : 244.26
SMILES Code : O=C(O)C(C)C1=CC=C(C2=CC=CC=C2)C(F)=C1
Synonyms :
dl-Flurbiprofen; Ansaid; Flurbiprofen, Ansaid, Froben, Cebutid, Antadys
MDL No. :MFCD00079303

Safety of Flurbiprofen

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H361
Precautionary Statements:P201-P202-P264-P270-P280-P301+P310+P330-P308+P313-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rabbit skin 150 mg 24 hours Evaluate the penetration enhancement effect of GER-C14 on Flurbiprofen, results showed GER-C14 had the best penetration promotion effect. Asian J Pharm Sci. 2022 Jan;17(1):139-152
HCA-7 cells 11.7 µM 16 hours R-flurbiprofen inhibited PGE2 release in HCA-7 cells with an IC50 of 11.7 µM. Int J Mol Sci. 2016 Dec 30;18(1):68
A-549 cells 5.6 µM 16 hours R-flurbiprofen inhibited PGE2 release in A-549 cells with an IC50 of 5.6 µM. Int J Mol Sci. 2016 Dec 30;18(1):68
HeLa cells 5.1 µM 16 hours R-flurbiprofen inhibited PGE2 release in HeLa cells with an IC50 of 5.1 µM. Int J Mol Sci. 2016 Dec 30;18(1):68
B103 murine neuronal cell line 400 μM or 1 mM 6 and 9 hours post-infection Flurbiprofen in combination with the caspase inhibitor Z-VAD-fmk drastically reduced HSV-1-induced Aβ42 oligomer production. Transl Psychiatry. 2023 Mar 10;13(1):86
Caco-2 cells 0, 0.5, 2.5, 5, 25, 50 µg/mL (corresponds to 0, 2, 10.2, 20.5, 102.3, 204.7 µM) 24 h or 48 h To investigate the effect of flurbiprofen on ACE2 mRNA and protein expression. Results showed flurbiprofen did not alter ACE2 mRNA expression but slightly increased ACE2 protein expression. Int J Mol Sci. 2022 Jan 19;23(3):1049
C6 glial cells 200 µM 4 hours To assess the effect of FP-loaded dendrimeric delivery systems on γ-secretase enzyme activity. Results showed that FP and FP-dendrimer complexes significantly reduced γ-secretase activity. Int J Mol Sci. 2018 Oct 18;19(10):3224
bEnd.3 cells 25 to 400 µM 24 and 48 hours To evaluate the cytotoxicity and biocompatibility of FP-loaded dendrimeric delivery systems. Results showed cell viability exceeding 70% at concentrations up to 400 µM, indicating these delivery systems were non-toxic to these cells. Int J Mol Sci. 2018 Oct 18;19(10):3224

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Japanese white rabbits Transdermal delivery model Transdermal administration 208.8 mg Single dose, 48 hours duration Evaluate the pharmacokinetic impact of GER-C14 on Flurbiprofen, results showed GER-C14 significantly increased Cmax and AUC0-48. Asian J Pharm Sci. 2022 Jan;17(1):139-152
Sprague-Dawley rats Collagenase II-induced knee osteoarthritis model Intra-articular injection 0.5 mg/time Every 72 hours for 7 times To evaluate the therapeutic effects of flurbiprofen thermogel in a knee osteoarthritis model, showing significant reduction in pain and inflammatory response. Drug Deliv. 2020 Dec;27(1):1034-1043
Japanese white rabbits Transdermal delivery model Transdermal administration 208.8 mg FP Single dose, 48 hours duration To evaluate the transdermal enhancement effect of GER-C14 in vivo. Results showed that the GER-C14 group had the highest AUC0–48, indicating the strongest transdermal enhancement effect. Asian J Pharm Sci. 2022 Jan;17(1):139-152

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02191358 - Completed - United States, California ... More >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 Less <<
NCT03520907 Postoperative Pain ... More >> Inguinal Hernia Unilateral Children, Only Less << Not Applicable Recruiting April 2019 Japan ... More >> Ibaraki Children's Hospital Recruiting Mito, Ibaraki, Japan, 311-4145 Contact: Kazuhiko Okuyama, MD    81-29-254-1151    okuokukk@gmail.com    Principal Investigator: Yuki Takeda, MD          Sub-Investigator: Iwao Sukegawa, MD Less <<
NCT02784041 Osteoarthritis,Knee Not Applicable Unknown December 2018 China ... More >> Peking Union Medical College Hospital Beijing, China, 100730 Less <<
NCT03262051 - Recruiting September 1, 2018 Switzerland ... More >> Geneva University Hospitals, HUG Recruiting Genève, Switzerland Contact: Caroline Samer Less <<
NCT02789527 Healthy Not Applicable Completed - Czechia ... More >> Charles University in Prague/Faculty of Science/Department of Anthropology and Human Genetics Praha 2, Czechia, 128 43 Ethiopia Addis Ababa University/College of Health Sciences Addis Ababa, Ethiopia, P.O.Box 9086 Greece Democritus University of Thrace/School of Health Sciences/University Campus, Dragana Alexandroupolis, Greece, 68100 Oman Sultan Qaboos University/College of Medicine and Health Sciences/Department of Pharmacology Muscat, Oman, P. O. Box 50 Less <<
NCT00105547 Alzheimer Disease ... More >> Dementia Less << Phase 3 Completed - -
NCT00380276 Alzheimer's Disease Phase 3 Terminated(Myriad has disconti... More >>nued the development of Flurizan.) Less << December 2008 -
NCT00322036 Alzheimer Disease ... More >> Dementia Less << Phase 3 Terminated(Myriad has disconti... More >>nued the development of Flurizan.) Less << December 2008 -
NCT00920088 Healthy Subjects ... More >> Infection, Human Immunodeficiency Virus Less << Phase 1 Completed - United States, Maryland ... More >> GSK Investigational Site Baltimore, Maryland, United States, 21225 Less <<
NCT00078104 Healthy Tooth... More >> Extraction Less << Phase 2 Completed - United States, Maryland ... More >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Less <<
NCT00519246 Pain, Postoperative ... More >> Mastectomy Less << Phase 4 Completed - China, Jiangsu ... More >> Nanjing Maternal and Child Care Hospital Nanjing, Jiangsu, China, 210004 Less <<
NCT02438072 Depression Not Applicable Unknown December 2015 Switzerland ... More >> Hôpitaux Universitaires de Genève Recruiting Genève, Switzerland, 1205 Contact: celia Lloret-Linares, MD, PhD    0041 79 55 36 389    celia.LloretLinares@hcuge.ch Less <<
NCT00078364 Healthy Tooth... More >> Extraction Less << Phase 2 Completed - United States, Maryland ... More >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Less <<
NCT00088686 Healthy Tooth... More >> Extraction Less << Phase 2 Completed - United States, Maryland ... More >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Less <<
NCT01346800 Healthy Volunteers Phase 1 Completed - Switzerland ... More >> University Hospitals Geneva 14, Switzerland, 1211 Less <<
NCT02403687 - Completed - -
NCT01535079 Acute Sore Throat Pain Phase 2 Completed - France ... More >> Eurofins Optimed Gières, France Eurofins Optimed Lyon Pierre Bénite, France Germany Erfurt, Germany United Kingdom Cardiff, United Kingdom Less <<
NCT02984865 Postoperative Nausea and Vomit... More >>ing Surgery Anesthesia Peritoneal Dialysis Rectus Sheath Block Less << Not Applicable Recruiting May 1, 2018 China, Anhui ... More >> the First Affiliated Hospital of Anhui Medical University Recruiting Hefei, Anhui, China, 230032 Contact: yu mao    +86 18019951656    maoyu163flying@163.com Less <<
NCT01731067 Healthy Volunteers Phase 1 Completed - Switzerland ... More >> University Hospitals Geneva 14, Switzerland Less <<
NCT00964106 Drug Interactions Phase 1 Completed - Korea, Republic of ... More >> GSK Investigational Site Busan, Korea, Republic of, 614-735 GSK Investigational Site Seoul, Korea, Republic of, 110-744 Less <<
NCT00443170 Healthy Subjects ... More >> Anaemia Less << Phase 1 Completed - Australia, New South Wales ... More >> GSK Investigational Site Randwick, Sydney, New South Wales, Australia, 2031 Australia, Queensland GSK Investigational Site Herston, Queensland, Australia, 4006 Australia, South Australia GSK Investigational Site Adelaide, South Australia, Australia, 5000 Less <<
NCT02094339 Pain Complica... More >>tions Less << Phase 4 Unknown June 2016 China, Guangdong ... More >> Guangzhou Military Region General Hospital, Department of Anesthesiology Recruiting Guangzhou, Guangdong, China, 510010 Contact: Tao Zhi Li    15625052815 ext 86    lytow@qq.com Less <<
NCT01872494 Pain Phase 4 Completed - China, Guangdong ... More >> Guangzhou Military Region General Hospital, Department of Anesthesiology Guangzhou, Guangdong, China, 510010 Less <<
NCT02300480 Post-operative Pain ... More >> Gallstone Disease Less << Phase 4 Unknown November 2015 China, Chongqing ... More >> China,Chongqing The First Affiliated Hospital of Chongqing Medical University Not yet recruiting Chongqing, Chongqing, China, 400016 Contact: Su Min, MD    +86-23-89011068    ms89011068@163.com    Contact: Dong Zhang, Master    +86-23-89011061    zdcqmua420@163.com Less <<
NCT00615212 Diabetes Mellitus, Type 2 Phase 1 Completed - United States, New York ... More >> GSK Investigational Site Buffalo, New York, United States, 14202 Less <<
NCT02604797 C.Delivery; Surgery (Previous)... More >>, Gynecological Less << Not Applicable Unknown January 2018 -
NCT02045966 Hepatitis C Phase 1 Completed - -
NCT00083356 Tooth, Impacted Phase 2 Completed - United States, Maryland ... More >> National Institute of Nursing Research (NINR) Bethesda, Maryland, United States, 20892 Less <<
NCT02595333 C.Delivery; Surgery (Previous)... More >>, Gynecological Less << Not Applicable Unknown December 2017 -
NCT03720366 Leukemia, Myeloid, Acute Phase 1 Not yet recruiting December 30, 2022 -
NCT01061112 - Unknown June 2014 United States, Minnesota ... More >> Clinical and Translational Science Institute Minneapolis, Minnesota, United States, 55414 Less <<
NCT00045123 Prostate Cancer Phase 2 Unknown - -
NCT02114463 Pain Complica... More >>tions Less << Phase 4 Unknown August 2016 China, Guangdong ... More >> Guangzhou Military Region General Hospital, Department of Anesthesiology Recruiting Guangzhou, Guangdong, China, 510010 Contact: Dong Xu Zhou    13268260337 ext 86    13268260337@163.com Less <<
NCT02762123 Rheumatoid Arthritis Phase 1 Completed - United States, Texas ... More >> Ppd Development, Lp Austin, Texas, United States, 78744 Less <<
NCT02670954 Postoperative Sedation, Abdomi... More >>nal Surgery Less << Not Applicable Completed - China, Jiangsu ... More >> Institute of General Surgery of Jinling Hospital Nanjing, Jiangsu, China, 210002 Less <<
NCT02578277 HIV Infections Phase 1 Completed - United States, Texas ... More >> GSK Investigational Site Austin, Texas, United States, 78744 Less <<
NCT02674737 Postoperative Sedation,Gastrec... More >>tomy, Enhanced Recovery After Surgery Less << Not Applicable Unknown - China, Jiangsu ... More >> Institute of General Surgery of Jinling Hospital Recruiting Nanjing, Jiangsu, China, 210002 Contact: Wenkui Yu, Ph.D.    13701582986    yudrnj@163.com Less <<
NCT03131973 Rheumatoid Arthritis Phase 1 Completed - United States, Texas ... More >> PPD Development, LP Austin, Texas, United States, 78744 Less <<
NCT03147066 Catheter Related Bladder Disco... More >>mfort Less << Phase 4 Completed - China, Jiangsu ... More >> Zhongda Hospital Nanjing, Jiangsu, China, 210009 Less <<
NCT01026714 Healthy Volunteers Phase 1 Phase 2 Completed - Switzerland ... More >> University Hospitals Geneva 14, Switzerland, 1211 Less <<
NCT03090009 Peri-implant Mucositis Early Phase 1 Not yet recruiting April 2020 Israel ... More >> Hadassah Medical Organization Not yet recruiting Jerusalem, Israel Less <<
NCT02043366 Pain Anesthes... More >>ia Less << Not Applicable Completed - China, Tianjin ... More >> Tianjin Medical University General Hospital Tianjin, Tianjin, China, 300052 Less <<
NCT03745599 Pain Quality ... More >>of Life Less << Phase 4 Completed - Turkey ... More >> Abdullah AlAlwani Mersin, Turkey, 99010 Less <<
NCT01998217 Pancreatic Stone Disease Phase 4 Completed - China, Shanghai ... More >> Department of Anesthesiology, Changhai Hospital Shanghai, Shanghai, China, 200433 Less <<
NCT02043366 - Completed - -
NCT02569905 Postoperative Shivering Phase 4 Completed - China, Guangxi ... More >> Anesthesia Department, Tumor Hospital of Guangxi Medical University Nanning, Guangxi, China, 530021 Less <<
NCT00425451 Periodontitis Phase 2 Completed - Israel ... More >> Hadassah Medical Organization Jerusalem, Israel, 91120 Less <<
NCT01040286 Periodontitis Phase 2 Completed - Israel ... More >> Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center Haifa, Israel, 9602 Less <<
NCT02456844 Rheumatoid Arthritis Phase 1 Completed - -
NCT03562611 Surgery Anest... More >>hesia Pain Less << Not Applicable Recruiting September 30, 2018 China, Guangdong ... More >> Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510000 Contact: Huijing Ye, Master    00862087331539    yehuijing@qq.com    Contact: Huasheng Yang, Doctor    00862087331539    yanghs64@126.com Less <<
NCT03014713 Patient-Controlled Analgesia Phase 4 Recruiting December 2017 China, Guangdong ... More >> Guangzhou General Hospital of Guangzhou Military Command Recruiting Guangzhou, Guangdong, China, 510010 Contact: Weifeng Tu    +8613922116606    wftuyx02@163.com    Contact: Chuangbo Xie    +8615521118558    xiechuangbo@126.com    Principal Investigator: Weifeng Tu, PhD          Sub-Investigator: Yang Zhou, PhD          Sub-Investigator: Chuangbo Xie, Master Less <<
NCT01986361 Acute Pharyngitis ... More >> Sore Throat Less << Phase 3 Completed - United States, Connecticut ... More >> University of Connecticut - Student Health Services Storrs, Connecticut, United States, 06269-4011 Less <<
NCT02367937 Healthy Phase 1 Completed - United Kingdom ... More >> Covance Clinical research Unit (CRU) Ltd,Springfield House, Hyde street Leeds, United Kingdom, LS2 9LH Less <<
NCT00001724 Pain PHASE2 COMPLETED 2025-11-01 National Institute of Dental A... More >>nd Craniofacial Research (NIDCR), Bethesda, Maryland, 20892, United States Less <<
NCT02391688 Drug Interaction Phase 1 Completed - Switzerland ... More >> Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4 Genève, Switzerland, 1211 Less <<
NCT01048866 - Completed - -
NCT00725218 Postoperative Pain Phase 4 Completed - China, Jiangsu ... More >> Nanjing Maternal and Child Health Care Hospital Nanjing, Jiangsu, China, 210004 Less <<
NCT00759330 Chronic Low Back Pain Phase 2 Completed - United States, Arizona ... More >> Redpoint Research Phoenix, Arizona, United States, 85029 United States, California Diablo Clinical Research, Inc. Walnut Creek, California, United States, 94598 United States, Florida University Foundation for Education and Research, Inc. Tampa, Florida, United States, 33606 Palm Beach Research Center West Palm Beach, Florida, United States, 33409 United States, Tennessee Internal Medicine Associates of Cordova Cordova, Tennessee, United States, 38018 Sarah Cannon Research Institute Memphis, Tennessee, United States, 38119 United States, Texas Senior Adults Specialty Research Austin, Texas, United States, 78757 United States, Virginia Charolettesville Medical Research Charlottesville, Virginia, United States, 22911 United States, Washington Rainier Clinical Research Center, Inc. Renton, Washington, United States, 98057 United States, Wisconsin Aurora Advanced Healthcare, Inc. Milwaukee, Wisconsin, United States, 53209 Less <<
NCT01986361 - Completed - -
NCT01048866 Pharyngitis Phase 3 Completed - United States, New York ... More >> Bluestone Center for Clinical Research New York, New York, United States, 10010 Less <<
NCT00759330 - Completed - -
NCT03200600 Carcinoma, Non-Small-Cell Lung... More >> Surgery--Complications Dexamethasone Flubiprofen Axetil Delirium Less << Phase 4 Recruiting September 30, 2019 China, Beijing ... More >> Peking University First Hospital Recruiting Beijing, Beijing, China, 100035 Contact: Guangyu Liu, MD    +8613552317363    liuguangyu@bjmu.edu.cn    Beijing Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yunxiao Zhang, MD    +8615210626283    yunxiao304@163.com Less <<
NCT02227173 Drug-drug Interaction Study Phase 1 Completed - United States, Texas ... More >> Healthcare Discoveries, LLC d/b/a ICON Development Solutions San Antonio, Texas, United States, 78209 Less <<
NCT01049334 - Completed - -
NCT01910090 Healthy Phase 1 Completed - Jordan ... More >> Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit Amman, Jordan, 00962 Less <<
NCT03172988 Carcinoma, Non-Small-Cell Lung... More >> Surgery Dexamethasone Flubiprofen Axetil Long-term Effects Secondary to Cancer Therapy in Adults Less << Phase 4 Recruiting August 30, 2023 China, Beijing ... More >> Peking University First Hospital Recruiting Beijing, Beijing, China, 100035 Contact: Guangyu Liu, MD    +8613552317363    liuguangyu@bjmu.edu.cn    Beijing Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yunxiao Zhang, MD    +8615210626283    yunxiao304@163.com Less <<
NCT03171987 Acute Back Pain Phase 4 Recruiting June 30, 2019 Taiwan ... More >> Jen-Yuh Chen Recruiting Taipei, Please Select, Taiwan, 11031 Contact: JEN-YUH CHEN, MD    +8862395-6755    bonechen2010@gmail.com    Taipei Medical University Hospital Recruiting Taipei, Please Select, Taiwan, 110 Contact: Meng-Huang Wu, MD    +886227372181 ext 3740    maxwutmu@gmail.com    Contact: Shiao-Wei Ku, BS    +886227372181 ext 3740    weiwei820116@gmail.com    Principal Investigator: Meng-Huang Wu, MD Less <<
NCT03422887 Surgery Anest... More >>hesia Pain Less << Not Applicable Recruiting September 30, 2018 China, Guangdong ... More >> Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510000 Contact: Huijing Ye, Master    00862087331539    yehuijing@qq.com    Contact: Huasheng Yang, Doctor    00862087331539    yanghs64@126.com Less <<
NCT03165929 Surgery, Oral Early Phase 1 Completed - -
NCT02206854 Healthy Volunteers Phase 1 Completed - Germany ... More >> Johann Wolfgang Goethe University Hospital Frankfurt, Germany, 60528 Less <<
NCT01049334 Pharyngitis Phase 3 Completed - United States, Connecticut ... More >> University of Connecticut, Student Health Services Storrs, Connecticut, United States, 06268 Less <<
NCT06238154 Oral Soft Tissue Conditions|Dr... More >>ug Effect|Drug Use Less << PHASE4 COMPLETED 2024-01-20 Yuzuncu Yil University, Van, M... More >>erkez, 65090, Turkey Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.09mL

0.82mL

0.41mL

20.47mL

4.09mL

2.05mL

40.94mL

8.19mL

4.09mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories